Latest From Bracco SPA
French imaging agent specialist Guerbet is targeting multi-use markets to grow its diagnostic imaging business while continuing to build through acquisitions. While its diagnostic imaging revenues were about flat in 2018, its imaging intervention business grew almost 19% in constant currency compared to 2017.
The global market for diagnostic and guided interventional cardiology products is expected to reach $4.8bn by 2021, and is driven in large part by the rising elderly population and increasing burden of cardiovascular disease (CVD). Meddevicetracker expects that intracardiac echocardiography (ICE), guide wire-based intravascular stenosis assessment (FFR) and optical coherence tomography (OCT) systems will drive overall market growth, given their high demand, which is supported by clinical evidence needed to bring cost savings and improved outcomes. Physicians' preference for using noninvasive and minimally invasive diagnostic techniques in cases where results are inconclusive is also changing the landscape of innovation. In this feature, we'll take a closer look at the overall market and its regional perspective, the competitive landscape of the three fastest-growing segments ICE, FFR and OCT, and the latest emerging technologies, as well as provide insight into what physicians think of these technologies.
Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
The latest drug development news and highlights from our FDA Performance Tracker.
- Diagnostic Equipment & Supplies
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Bracco SPA
- Senior Management
- Diana Bracco, Pres. & CEO
- Contact Info
Phone: (39) 02 21771
Via Egidio Folli 50